[HTML][HTML] British Thoracic Society guidelines for the investigation and management of pulmonary nodules: accredited by NICE
This guideline is based on a comprehensive review of the literature on pulmonary nodules
and expert opinion. Although the management pathway for the majority of nodules detected …
and expert opinion. Although the management pathway for the majority of nodules detected …
The integration of radiotherapy with immunotherapy for the treatment of non–small cell lung cancer
Five-year survival rates for non–small cell lung cancer (NSCLC) range from 14% to 49% for
stage I to stage IIIA disease, and are< 5% for stage IIIB/IV disease. Improvements have been …
stage I to stage IIIA disease, and are< 5% for stage IIIB/IV disease. Improvements have been …
Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials
Background The standard of care for operable, stage I, non-small-cell lung cancer (NSCLC)
is lobectomy with mediastinal lymph node dissection or sampling. Stereotactic ablative …
is lobectomy with mediastinal lymph node dissection or sampling. Stereotactic ablative …
Treatment of stage I and II non-small cell lung cancer: Diagnosis and management of lung cancer: American College of Chest Physicians evidence-based clinical …
Background The treatment of stage I and II non-small cell lung cancer (NSCLC) in patients
with good or low surgical risk is primarily surgical resection. However, this area is …
with good or low surgical risk is primarily surgical resection. However, this area is …
Survival outcome after stereotactic body radiation therapy and surgery for stage I non-small cell lung cancer: a meta-analysis
Purpose This study compared treatment outcomes of stereotactic body radiation therapy
(SBRT) with those of surgery in stage I non-small cell lung cancer (NSCLC). Methods and …
(SBRT) with those of surgery in stage I non-small cell lung cancer (NSCLC). Methods and …
Lobectomy, sublobar resection, and stereotactic ablative radiotherapy for early-stage non–small cell lung cancers in the elderly
Importance The incidence of early-stage non–small cell lung cancer (NSCLC) among the
elderly is expected to rise dramatically owing to demographic trends and increased …
elderly is expected to rise dramatically owing to demographic trends and increased …
[HTML][HTML] Stage I–II non-small-cell lung cancer treated using either stereotactic ablative radiotherapy (SABR) or lobectomy by video-assisted thoracoscopic surgery …
Background Video-assisted thoracoscopic surgery (VATS) lobectomy and stereotactic
ablative radiotherapy (SABR) are both used for early-stage non-small-cell lung cancer. We …
ablative radiotherapy (SABR) are both used for early-stage non-small-cell lung cancer. We …
A critical review of recent developments in radiotherapy for non-small cell lung cancer
S Baker, M Dahele, FJ Lagerwaard, S Senan - Radiation oncology, 2016 - Springer
Lung cancer is the leading cause of cancer mortality, and radiotherapy plays a key role in
both curative and palliative treatments for this disease. Recent advances include stereotactic …
both curative and palliative treatments for this disease. Recent advances include stereotactic …
Comparative effectiveness of 5 treatment strategies for early-stage non-small cell lung cancer in the elderly
PURPOSE: The incidence of early-stage non-small cell lung cancer (NSCLC) among older
adults is expected to increase because of demographic trends and computed tomography …
adults is expected to increase because of demographic trends and computed tomography …
7‐year follow‐up after stereotactic ablative radiotherapy for patients with stage I non–small cell lung cancer: Results of a phase 2 clinical trial
B Sun, ED Brooks, RU Komaki, Z Liao, MD Jeter… - Cancer, 2017 - Wiley Online Library
BACKGROUND The authors evaluated the efficacy, patterns of failure, and toxicity of
stereotactic ablative radiotherapy (SABR) for patients with medically inoperable, clinical …
stereotactic ablative radiotherapy (SABR) for patients with medically inoperable, clinical …